Cascadian Therapeutics Inc (CASC) Receives Consensus Rating of “Hold” from Brokerages

Cascadian Therapeutics Inc (NASDAQ:CASC) has earned an average rating of “Hold” from the eight research firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $7.00.

Several research firms recently issued reports on CASC. ValuEngine raised Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 31st. BidaskClub raised Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Raymond James Financial cut Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Zacks Investment Research cut Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $10.00 target price on Cascadian Therapeutics and gave the stock a “hold” rating in a research note on Friday, March 9th.

How to Become a New Pot Stock Millionaire

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in shares of Cascadian Therapeutics by 6,622.8% in the third quarter. JPMorgan Chase & Co. now owns 89,413 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 88,083 shares during the last quarter. Unterberg Capital LLC bought a new stake in shares of Cascadian Therapeutics in the fourth quarter worth about $370,000. Northern Trust Corp grew its stake in shares of Cascadian Therapeutics by 415.5% in the second quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock worth $1,420,000 after purchasing an additional 308,270 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of Cascadian Therapeutics in the fourth quarter worth about $207,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Cascadian Therapeutics by 203.7% in the second quarter. Dimensional Fund Advisors LP now owns 97,880 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 65,651 shares during the last quarter. 81.38% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CASC traded down $0.04 on Friday, reaching $9.98. 2,000 shares of the company traded hands, compared to its average volume of 1,092,996. Cascadian Therapeutics has a 52 week low of $3.18 and a 52 week high of $10.21.

TRADEMARK VIOLATION NOTICE: “Cascadian Therapeutics Inc (CASC) Receives Consensus Rating of “Hold” from Brokerages” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://ledgergazette.com/2018/04/13/cascadian-therapeutics-inc-casc-receives-consensus-rating-of-hold-from-brokerages.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply